Advertisement

Kardiovaskuläre Pharmaka und körperliche Belastung

Chapter
  • 2k Downloads

Auszug

Medikamente und körperliche Aktivität können sich ergänzen. In vielen Fällen können bei gleichzeitigem regelmäßigem Training Medikamente eingespart werden, beispielsweise um einen erhöhten Blutdruck zu normalisieren. Andererseits müssen aber auch Interaktionen beachtet werden, die sich nicht fördernd, sondern hemmend auswirken [49, 90].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aigner A, Muß N, Krempler F, Femminger H, Sandhofer F (1983) Einfluss einer akuten Beta1-und Beta1/2-Rezeptoren-Blockade auf den Kohlenhydrat-und Fettstoffwechsel unter Belastungenbedingungen. Dtsch Med Wochenschr 108: 293–298PubMedGoogle Scholar
  2. 2.
    Alvarado RG, Liu JY, Zwolak RM (2001) Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg 34:1123–1126PubMedCrossRefGoogle Scholar
  3. 3.
    Ammar EM, Said SA, Hassan MS (2004) Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res 50:253–259PubMedCrossRefGoogle Scholar
  4. 4.
    Andersson KE (1982) Effects of calcium and calcium antagonists on the excitation-contraction coupling in striated and smooth muscle. Acta Pharmacol Toxicol 43(Suppl1):5–14Google Scholar
  5. 5.
    Appleby M, Fisher M, Martin M (1994) Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol 44:171–174PubMedCrossRefGoogle Scholar
  6. 6.
    Bahrke MS, Yesalis CE, Brower KJ (1998) Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child Adolesc Psychiatr Clin N Am 7:821–838PubMedGoogle Scholar
  7. 7.
    Bouchard R, Weber AR, Geiger JD (2002) Informed decision-making on sympathomimetic use in sport and health. Clin J Sport Med 12:209–224PubMedCrossRefGoogle Scholar
  8. 8.
    Bowman S (1990) Anabolic steroids and infarction. Br Med J 300:750Google Scholar
  9. 9.
    Colao A, Marzullo P, Di Somma C, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol 54:137–154CrossRefGoogle Scholar
  10. 10.
    Cunha TS, Moura MJ, Bernardes CF, Tanno AP, Marcondes FK (2005) Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment. Hypertension 46:1010–1015PubMedCrossRefGoogle Scholar
  11. 11.
    De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991) Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med 12: 408–412PubMedGoogle Scholar
  12. 12.
    Di Bello V, Giorgi D, Bianchi M, Bertini A, Caputo MT, Valenti G, Furioso O, Alessandri L, Paterni M, Giusti C (1999) Effects of anabolic-androgenic steroids on weight-lifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc 31:514–521PubMedCrossRefGoogle Scholar
  13. 13.
    Dickerman RD, Schaller F, Prather I, McConathy WJ (1995) Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 86:172–173PubMedGoogle Scholar
  14. 14.
    Duffey DJ, Horwitz DL, Brammel HL (1984) Nifedipine and the conditioning response. Am J Cardiol 53:908–911PubMedCrossRefGoogle Scholar
  15. 15.
    Ebenbichler CF, Sturm W, Ganzer H, Bodner J, Mangweth B, Ritsch A, Sandhofer A, Lechleitner M, Foger B, Patsch JR (2001) Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158:483–490PubMedCrossRefGoogle Scholar
  16. 16.
    Ekblom B, Goldberg AN, Kilbom A, Astrand PO (1972) Effect of atropine and propranolol on the oxygen transport system during exercise in man. Scand J Clin Lab Invest 30:35–43PubMedCrossRefGoogle Scholar
  17. 17.
    El-Sayed MS, El-Sayed Ali Z, Ahmadizad S (2004) Exercise and training effects on blood haemostasis in health and disease: an update. Sports Med 34:181–200PubMedCrossRefGoogle Scholar
  18. 18.
    Fahrenbach MC, Yurgalevitch SM, Zmuda JM, Thompson PD (1995) Effect of doxazosin or atenolol on exercise performance in physically active, hypertensive men. Am J Cardiol 75:258–263PubMedCrossRefGoogle Scholar
  19. 19.
    Falkenberg M, Karlsson J, Örtenwall P (1997) Peripheral arterial thrombosis in two young men using anabolic steroids. Eur J Vasc Endovasc Surg 13:223–226PubMedCrossRefGoogle Scholar
  20. 20.
    Fellenius E (1983) Muscle fatigue and beta-blockers — a review. Int J Sports Med 4:1–8PubMedGoogle Scholar
  21. 21.
    Ferenchick GS (1991) Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses 35:27–31PubMedCrossRefGoogle Scholar
  22. 22.
    Ferenchick GS (1991) Association of steroid abuse with cardiomyopathy in athletes. Am J Med 91:562PubMedCrossRefGoogle Scholar
  23. 23.
    Ferenchick G, Schwartz D, Ball M, Schwartz K (1992) Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 303:78–82PubMedCrossRefGoogle Scholar
  24. 24.
    Ferrer M, Encabo A, Marin J, Balfagon G (1994) Treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 252:233–241PubMedCrossRefGoogle Scholar
  25. 25.
    Ferrera PC, Putnam DL, Verdile VP (1997) Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology 88:218–220PubMedGoogle Scholar
  26. 26.
    Fineschi V, Baroldi G, Monciotti F, Paglicci Reatelli L, Turilazzi E (2001) Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 125:253–255PubMedGoogle Scholar
  27. 27.
    Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SB (2005) Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 15:1–6Google Scholar
  28. 28.
    Fisher M, Appleby M, Rittoo D, Cotter L (1996) Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract 50:222–223PubMedGoogle Scholar
  29. 29.
    Frankle MA, Eichberg R, Zachariah SB (1988) Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 69:632–633PubMedGoogle Scholar
  30. 30.
    Franz IW, Lohmann FW (1979) Der Einfluss einer chronischen sog. kardioselektiven und nicht kardioselektiven Beta-Rezeptorenblockade auf den Blutdruck, die Sauerstoffaufnahme und den Kohlenhydratstoffwechsel. Z Kardiol 68:503–509PubMedGoogle Scholar
  31. 31.
    Fröhlich J, Kullmer T, Urhausen A, Bergmann R, Kindermann W (1989) Lipid profile of body builders with and without self-administration of anabolic steroids. Eur J Appl Physiol 59:98–103CrossRefGoogle Scholar
  32. 32.
    Furlanello F, Bentivegna S, Cappato R, De Ambroggi L (2003) Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J 4:829–837PubMedGoogle Scholar
  33. 33.
    Garg R, Yusuf S for the Collaborative Group on ACE Inhibitor Trials (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273:1450–1456PubMedCrossRefGoogle Scholar
  34. 34.
    Gillin AG, Fletcher PJ, Horvath JS, Hutton BF, Bautovich GJ, Tiller DJ (1989) Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function. Am J Cardiol 63:950–954PubMedCrossRefGoogle Scholar
  35. 35.
    Glazer G (1991) Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 151:1925–1933PubMedCrossRefGoogle Scholar
  36. 36.
    Godon P, Bonnefoy E, Guerard S, Munet M, Velon S, Brion R, Touboul P (2000) Myocardial infarction and anabolic steroid use. A case report. Arch Mal Coeur Vaiss 93:879–883PubMedGoogle Scholar
  37. 37.
    Goldstein DR, Dobbs T, Krull B, Plumb VJ (1998) Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 91:780–784PubMedGoogle Scholar
  38. 38.
    Gordon NF (1985) Effect of selective and nonselective beta-adrenoceptor blockade on thermoregulation during prolonged exercise in heat. Am J Cardiol 55:74D–78DPubMedCrossRefGoogle Scholar
  39. 39.
    Gordon NF, Scott CB, Duncan JJ (1997) Effects of atenolol vs enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. Am J Cardiol 79:1065–1069PubMedCrossRefGoogle Scholar
  40. 40.
    Grace F, Sculthorpe N, Baker J, Davies B (2003) Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport 6:307–312PubMedCrossRefGoogle Scholar
  41. 41.
    Howard PA, Cheng JW, Crouch MA, Colucci VJ, Kalus JS, Spinler SA, Munger M (2006) Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure. Ann Pharmacother 40:1607–1616PubMedCrossRefGoogle Scholar
  42. 42.
    Huie MJ (1994) An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc 26:408–413PubMedGoogle Scholar
  43. 43.
    Joreteg T, Jogestrand T (1983) Physical exercise and digoxin binding to skeletal muscle: relation to exercise intensity. Eur J Clin Pharmacol 25:585–588PubMedCrossRefGoogle Scholar
  44. 44.
    Kaiser P (1984) Physical performance and muscle metabolism during β-adrenergic blockade in man. Acta Physiol Scand 536(Suppl):1–53Google Scholar
  45. 45.
    Kaiser P, Rössner S, Karlsson J (1981) Effect of beta-adrenergic blockade on endurance and short-time performance in respect to individual muscle fibre composition. Int J Sports Med 2:37–42PubMedCrossRefGoogle Scholar
  46. 46.
    Karhunen MK, Rämö MP, Kettunen R (1988) Anabolic steroids alter the haemodynamic effects of endurance training and deconditioning in rats. Acta Physiol Scand 133:297–306PubMedCrossRefGoogle Scholar
  47. 47.
    Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA (2003) Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 24:337–343PubMedCrossRefGoogle Scholar
  48. 48.
    Kennedy MC, Lawrence C (1993) Anabolic steroid abuse and cardiac death. Med J Aust 158:346–348PubMedGoogle Scholar
  49. 49.
    Keul J, Kindermann W (1976) Körperliche Aktivität und Pharmaka. Sportwissenschaft 6:425–450CrossRefGoogle Scholar
  50. 50.
    Kindermann W (1987) Calcium antagonists and exercise performance. Sports Med 4:177–193PubMedCrossRefGoogle Scholar
  51. 51.
    Kindermann W (2006) Kardiovaskuläre Nebenwirkungen von anabol-androgenen Steroiden. Herz 31:566–573PubMedCrossRefGoogle Scholar
  52. 52.
    Kindermann W, Simon G, Keul J (1979) The significance of the aerobic-anaerobic transition for the determination of work load intensities during endurance training. Eur J Appl Physiol 42:25–34CrossRefGoogle Scholar
  53. 53.
    Kindermann W, Salas-Fraire O, Sroka G, Müller U (1983) Serumenzymverhalten nach körperlicher Belastung-Abgrenzung von krankheitsbedingten Veränderungen. Herz/Kreisl 15:117–123Google Scholar
  54. 54.
    Kindermann W, Scheerer W, Salas-Fraire O, Biro G, Wölfing A (1984) Verhalten der körperlichen Leistungsfähigkeit und des Metabolismus unter akuter Beta1-und Beta1/2-Blockade. Z Kardiol 73:380–387PubMedGoogle Scholar
  55. 55.
    Kindermann W, Schmitt W, Stengele E (1985) Einfluss von Calcium-Antagonisten auf die körperliche Leistungsfähigkeit und den Metabolismus. Dtsch Med Wochenschr 110:1657–1661PubMedGoogle Scholar
  56. 56.
    Kindermann W, Schmitt W, Wölfing A (1986) Körperliche Leistungsfähigkeit, Metabolismus und hormonelles Verhalten unter Diltiazem. Z Kardiol 75:99–106PubMedGoogle Scholar
  57. 57.
    Kloner RA, Hale S, Alker K, Rezkalla S (1992) The effects of acute and chronic cocaine use on the heart. Circulation 85:407–419PubMedGoogle Scholar
  58. 58.
    Kullmer T, Kindermann W (1985) Physical performance and serum potassium under chronic beta-blockade. Eur J Appl Physiol 54:350–354CrossRefGoogle Scholar
  59. 59.
    Kullmer T, Kindermann W, Singer M (1987) Effects on physical performance of intrinsic sympathomimetic activity (ISA) during selective β1-blockade. Eur J Appl Physiol 56:292–298CrossRefGoogle Scholar
  60. 60.
    Lang R, Klein H, Weiss E, David D, Sareli P, Levy A, Guerrero J, di Segni E, Kaplinsky E (1983) Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 83:491–499PubMedCrossRefGoogle Scholar
  61. 61.
    Laroche G (1990) Steroid anabolic drugs and arterial complications in an athlete — a case history. Angiology 41:964–969PubMedCrossRefGoogle Scholar
  62. 62.
    La Rosée K, Schulz A, Böhm M, Erdmann E (1997) Kardiale Dekompensation eines Bodybuilders. Dtsch Med Wochenschr 122:1586–1590Google Scholar
  63. 63.
    LeGros T, McConnell D, Murry T, Edavettal M, Racey-Burns LA, Shepherd RE, Burns AH (2000) The effects of 17 alpha-methyltestosterone on myocardial function in vitro. Med Sci Sports Exerc 32:897–903PubMedCrossRefGoogle Scholar
  64. 64.
    Lehrl S, Blaha L, Spörl G (1977) Psychisches Befinden von Sportschützen im Training unter Placebo und Oxprenolol (Trasicor). Dtsch Z Sportmed 28:86–93Google Scholar
  65. 65.
    Ligueros M, Unwin R, Wilkins MR, Humphreys J, Coles SJ, Cleland J (1992) A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. Clin Auton Res 2:373–381PubMedCrossRefGoogle Scholar
  66. 66.
    Lisiewicz J, Fijalkowski P, Sankowski J (1999) Ischemic cerebral stroke and anabolic steroids (case report). Neurol Neurochir Pol 32:137–139PubMedGoogle Scholar
  67. 67.
    Lohmann FW (1981) Die Beeinflussung des Stoffwechsels durch Beta-Rezeptoren-Blocker. Klin Wochenschr 59:49–57PubMedCrossRefGoogle Scholar
  68. 68.
    Lombardo RM, Reina C, Abrignani MG, Rizzo PA, Braschi A, De Castro S (2006) Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 6:259–263PubMedCrossRefGoogle Scholar
  69. 69.
    Luke JL, Farb A, Virmani R, Sample RH (1990) Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci 35:1441–1447PubMedGoogle Scholar
  70. 70.
    Lyngberg KK (1991) Myocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger 153:587–588PubMedGoogle Scholar
  71. 71.
    McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ (1988) Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 62:16CrossRefGoogle Scholar
  72. 72.
    Melchert RB, Welder AA (1995) Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 27:1252–1262PubMedGoogle Scholar
  73. 73.
    Mewis C, Spyridopoulos I, Kuhlkamp V, Seipel L (1996) Manifestation of severe coronary heart disease after anabolic drug abuse. Clin Cardiol. 19:153–155PubMedGoogle Scholar
  74. 74.
    Mochizuki RM, Richter KJ (1988) Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Phys Sports Med 16:108–114Google Scholar
  75. 75.
    Moen MD, Wagstaff AJ (2006) Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 66:1389–1409PubMedCrossRefGoogle Scholar
  76. 76.
    Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, Heikkilä J (1996) Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 17:1576–1583PubMedGoogle Scholar
  77. 77.
    Nottin S, Nguyen LD, Terbah M, Obert P (2006) Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol 97:912–915PubMedCrossRefGoogle Scholar
  78. 78.
    Onder G, Vedova CD, Pahor M (2006) Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 12:2057–2064PubMedCrossRefGoogle Scholar
  79. 79.
    Palatini P, Bongiovi S, Mario L, Mormino P, Raule G, Pessina AC (1995) Effects of ACE-inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension. Eur J Clin Pharmacol 48:435–439PubMedCrossRefGoogle Scholar
  80. 80.
    Parkinson AB, Evans NA (2006) Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 38:644–651PubMedCrossRefGoogle Scholar
  81. 81.
    Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T (2000) Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 21:225–227PubMedCrossRefGoogle Scholar
  82. 82.
    Pedersen E, Madsen J, Kjaer K, Klitgaard N, Hvidt S (1983) Effects of physical activity and immobilization on plasma digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther 34:303–308PubMedCrossRefGoogle Scholar
  83. 83.
    Pesola MK (1988) Reversibility of the haemodynamic effects of anabolic steroids in rats. Eur J Appl Physiol 58:125–131CrossRefGoogle Scholar
  84. 84.
    Petersson A, Garle M, Granath F, Thiblin I (2006) Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. Drug Alcohol Depend 81:215–220PubMedCrossRefGoogle Scholar
  85. 85.
    Petri J, Arends BG, van Baak ML (1986) The effect of verapamil on cardiovascular and metabolic responses to exercise. Eur J Appl Physiol 55:499–502CrossRefGoogle Scholar
  86. 86.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRefGoogle Scholar
  87. 87.
    Predel HG, Mainka W, Schillings W, Knigge H, Montiel J, Fallois J, Agrawal R, Schramm T, Graf C, Giannetti BM, Bjarnason-Wehrens B, Prinz U, Rost RE (2001) Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 15:715–721PubMedCrossRefGoogle Scholar
  88. 88.
    Rämö P (1987) Anabolic steroids alter the haemodynamic responses of the canine left ventricle. Acta Physiol Scand 130:209–217PubMedGoogle Scholar
  89. 89.
    Raffestin B, Denjean A, Legrand A, Derrieux C, Boillot J (1985) Effects of nifedipine on responses to exercise in normal subjects. J Appl Physiol 58:702–709PubMedCrossRefGoogle Scholar
  90. 90.
    Rost R (1991) Sport-und Bewegungstherapie bei inneren Krankheiten. Deutscher Ärzte Verlag, Köln, S 217–23Google Scholar
  91. 91.
    Rusko H, Kantola H, Luhtanen P, Pulli M, Videman T, Viitasalo JT (1980) Effect of beta-blockade on performances requiring force, velocity, coordination and/or anaerobic metabolism. J Sports Med Phys Fitness 20:139–144PubMedGoogle Scholar
  92. 92.
    Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofschire PJ (1993) The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 25:1240–1245PubMedGoogle Scholar
  93. 93.
    Sahraian MA, Mottamedi M, Azimi AR, Moqhimi B (2004) Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report. BMC Neurol 4:22PubMedCrossRefGoogle Scholar
  94. 94.
    Schenk GK, Lang E, Anlauf M (1981) Beta-receptor-blocking therapy in hypertensive patients — effects on vigilance and behaviour. Aviat Space Environm Med 52:35–39Google Scholar
  95. 95.
    Schnabel A, Kindermann W, Salas-Fraire O, Cassens J, Steinkraus V (1983) Effect of beta-adrenergic blockade on supramaximal exercise capacity. Int J Sports Med 4:278–281PubMedGoogle Scholar
  96. 96.
    Schwarz L, Hegenauer K, Lieblang-Alff S, Kindermann W (1993) Einfluss von Ramipril auf körperliche Leistungsfähigkeit, metabolische Parameter und Belastungsblutdruck bei Gesunden. In Tittel K, Arndt K, Hollmann W (Hrsg) Sportmedizin gestern — heute — morgen. Barth, Leipzig Berlin Heidelberg, S 304–30Google Scholar
  97. 97.
    Siitonen L, Jänne J (1976) Effect of beta-blockade during bowling competition. Ann Clin Res 8:393–398PubMedGoogle Scholar
  98. 98.
    Stewart KJ, Effron MB, Valenti SA, Kelemen MH (1990) Effects of diltiazem or propranolol during exercise training of hypertensive men. Med Sci Sports Exerc 22:171–177PubMedGoogle Scholar
  99. 99.
    Striegel H, Simon P, Frisch S, Roecker K, Dietz K, Dickhuth HH, Ulrich R (2006) Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend 81:11–19PubMedCrossRefGoogle Scholar
  100. 100.
    Sundqvist K, Berglund B, Jogestrand T (1983) Effect of digoxin on physical performance in healthy man. Clin Physiol 3:205–208PubMedGoogle Scholar
  101. 101.
    Tesch PA (1985) Exercise performance and beta-blockade. Sports Med 2:389–412PubMedCrossRefGoogle Scholar
  102. 102.
    The Digitalis Investigation Group (DIG) (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533CrossRefGoogle Scholar
  103. 103.
    Thompson PD, Cullinane EM, Nugent AM, Sady MA, Sady SP (1989) Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers. Am J Med 86:104–109PubMedCrossRefGoogle Scholar
  104. 104.
    Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165–1168PubMedCrossRefGoogle Scholar
  105. 105.
    Tischer KH, Heyny-von Haussen R, Mall G, Doenecke P (2003) Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids. Z Kardiol 92:326–331PubMedCrossRefGoogle Scholar
  106. 106.
    Tokish JM, Kocher MS, Hawkins RJ (2004) Ergogenic aids: a review of basic science, performance, side effects, and status in sports. Am J Sports Med 32: 1543–1553PubMedCrossRefGoogle Scholar
  107. 107.
    Tomten SE, Kjeldsen SE, Nilsson S, Westheim AS (1994) Effect of alpha 1-adrenoceptor blockade on maximal VO2 and endurance capacity in well-trained athletic hypertensive men. Am J Hypertens 7:603–608PubMedGoogle Scholar
  108. 108.
    Torranin C, Smith DP, Byrd RJ (1979) Effect of acute termal dehydration and rapid rehydration on isometric and isotonic endurance. J Sports Med Phys Fitness 19:1–9PubMedGoogle Scholar
  109. 109.
    Trifunovic B, Norton GR, Duffield MJ, Avraam P, Woodiwiss AJ (1995) An androgenic steroid decreases left ventricular compliance in rats. Am J Physiol 268:H1096–1105PubMedGoogle Scholar
  110. 110.
    Urhausen A, Kindermann W (1992) Biochemical monitoring of training. Clin J Sports Med 2:52–61CrossRefGoogle Scholar
  111. 111.
    Urhausen A, Kindermann W (1999) Sports-specific adaptations and differentiation of the athlete’s heart. Sports Med 28:237–244PubMedCrossRefGoogle Scholar
  112. 112.
    Urhausen A, Albers T, Kindermann W (2004) Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 90:496–501PubMedCrossRefGoogle Scholar
  113. 113.
    Urhausen A, Hölpes R, Kindermann W (1989) One-and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 58: 633–640CrossRefGoogle Scholar
  114. 114.
    Urhausen A, Coen B, Weiler B, Kindermann W (1993) Individual anaerobic threshold and maximum lactate steady state. Int J Sports Med 14:134–139PubMedGoogle Scholar
  115. 115.
    Van Baak ML (1988) Beta-adrenoceptor blockade and exercise. Sports Med 6:209–255CrossRefGoogle Scholar
  116. 116.
    Videman T, Sonck T, Jänne J (1979) The effect of beta-blockade in ski-jumpers. Med Sci Sports Exerc 11:266–269Google Scholar
  117. 117.
    Vogt AM, Geyer H, Jahn L, Schänzer W, Kübler W (2002) Kardiomyopathie assoziiert mit unkontrollierter Selbstmedikation anaboler Steroide. Z Kardiol 91:357–362PubMedCrossRefGoogle Scholar
  118. 118.
    Wayne ED, Dominique E, Timothy DN (1993) Comparative effects of cilazapril and atenolol on maximal and prolonged submaximal exercise performance in hypertensive males. Am J Med 94:69–71CrossRefGoogle Scholar
  119. 119.
    Wolfel EE, Hiatt WR, Brammell HL, Travis V, Horwitz LD (1990) Plasma catecholamine responses to exercise after training with beta-adrenergic blockade. J Appl Physiol 68:586–593PubMedCrossRefGoogle Scholar
  120. 120.
    World-Anti-Doping Agency (WADA) The 2007 Prohibited List. www.wada-ama.org Google Scholar
  121. 121.
    Yesalis CE, Bahrke MS (2000) Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab 14:25–35PubMedCrossRefGoogle Scholar
  122. 122.
    Zuliani U, Bernardini B, Catapano A, Campana M, Cerioli G, Spattini M (1989) Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 10:62–66PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2007

Authors and Affiliations

  1. 1.Institut für Sport- und PräventivmedizinUniversität des SaarlandesSaarbrücken

Personalised recommendations